Treatment of light chain deposition disease with bortezomib and dexamethasone

Ítems similars

• Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone
  per: Efstathios Kastritis, et al.
  Publicat: (2019-10-01)
• Treatment of light chain deposition disease with bortezomib and dexamethasone
  per: Efstathios Kastritis, et al.
  Publicat: (2009-02-01)
• Cardiac and renal complications of carfilzomib in patients with multiple myeloma
  per: Meletios A. Dimopoulos, et al.
  Publicat: (2017-02-01)
• Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
  per: Efstathios Kastritis, et al.
  Publicat: (2007-04-01)
• Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma
  per: Evangelos Terpos, et al.
  Publicat: (2025-02-01)